Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
09:34am, Thursday, 05'th Feb 2026
The first week of February 2026 will be remembered as the day the pharmaceutical sector's most famous partnership officially dissolved. For years, Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S
First Look: AI shock hits software, Bitcoin breaks $70K, Disney names new CEO
07:38am, Thursday, 05'th Feb 2026
Stock News Bezos backs Post amid sweeping cuts: Amazon (AMZN) founder Jeff Bezos' Washington Post slashed roughly a third of staff and eliminated its Sports dep
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
08:00pm, Wednesday, 04'th Feb 2026
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez
05:46pm, Wednesday, 04'th Feb 2026
Seamus Fernandez, Guggenheim managing director, joins 'Power Lunch' to discuss the battle between Novo Nordisk and Eli Lilly.
Market Today: Tech Slump, Google AI Spend, Bitcoin Slide
05:35pm, Wednesday, 04'th Feb 2026
Guru Stock PicksAzvalor Internacional FI has made the following transactions:Reduce in XMAD: PSG by 98.37%Sold out in BAAdd in XMAD: COL by 6.77%New position in A
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
05:25pm, Wednesday, 04'th Feb 2026
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
04:26pm, Wednesday, 04'th Feb 2026
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Eli Lilly and Co (LLY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments Propel Future Outlook
04:05pm, Wednesday, 04'th Feb 2026
Full-Year Revenue: $65.2 billion, a 45% increase compared to 2024.Q4 Revenue Growth: 43% increase compared to Q4 2024.Gross Margin: 83.2% of revenue, consisten
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
02:02pm, Wednesday, 04'th Feb 2026
Over the last two days, Novo Nordisk A/S (NYSE: NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
01:15pm, Wednesday, 04'th Feb 2026
Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro so
Nasdaq Dips Over 400 Points; Eli Lilly Shares Surge Following Upbeat Earnings
12:32pm, Wednesday, 04'th Feb 2026
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 400 points on Wednesday.
Here's What Key Metrics Tell Us About Lilly (LLY) Q4 Earnings
12:30pm, Wednesday, 04'th Feb 2026
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare t
Eli Lilly's Strong Q4 Performance and Promising Outlook Propel Stock Higher
12:14pm, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) delivered an impressive performance in Q4 2025, driving its stock higher as it continues to lead in the obesity and diabetes treatment markets.
Eli Lilly Guides Up to 27% Sales Growth as Obesity Demand Surges
12:10pm, Wednesday, 04'th Feb 2026
Eli Lilly (LLY) has laid out a notably stronger sales outlook for the year, signaling continued momentum in the weight-loss market as demand for its obesity tre
Lilly Stock Jumps After Q4 Earnings Beat and Strong 2026 Guidance
11:25am, Wednesday, 04'th Feb 2026
LLY beats Q4 earnings and sales estimates as Mounjaro and Zepbound surge. Shares jump on stronger-than-expected revenue and EPS outlook for 2026.
